Subconjunctival Bevacizumab Injection in Glaucoma Filtering Surgery: A Case Control Series

Table 1

Characteristics of the subconjunctival bevacizumab (SCB) and control groups.

	SCB group	Control group	𝑃 value
Age (years)	71.5 ± 9.2	73.9 ± 7.4	0.21
Gender
Male	12	13	0.78
Female	16	15
Ethnicity
Caucasian	26 (92.8%)	27 (96.4%)
African decent	1 (3.6%)	1 (3.6%)	—
Asian	1 (3.6%)	0
Total patients	28	28
Eye
Right	19	17	0.60
Left	11	13
Total eyes	30	30
Diagnosis
Open-angle glaucoma	26 (86.7%)	25 (83.3%)
Ocular hypertension	2 (6.7%)	2 (6.7%)	0.90
Others (pigmentary,; pseudoexfoliation)	2 (6.7%)	3 (10%)
Total eyes	30	30
Surgery types
Phaco-NPGS	20 (66.7%)	24 (80%)
Phacotrabeculectomy	6 (20%)	3 (10%)	—
NPGS	3 (10%)	2 (6.7%)
Trabeculectomy	1 (3.3%)	1 (3.3%)
Total eyes	30	30
Preoperative IOP (mmHg)	19.6 ± 8.9	21.9 ± 9.8	0.51
Preoperative number of medications	3.0 ± 1.1	3.1 ± 1.0	0.48
Mean follow-up time (months)	16.9 ± 8.2	19.6 ± 11.5	0.16